

8 February 2006



## PharmAust Limited- TGA Audit

PharmAust Limited (ASX: PAA) notes that the market has been advised that the Company is in the process of seeking Therapeutic Goods Administration (TGA) registration of its manufacturing site in Welshpool WA for compliance with the Code of GMP For Medicinal Products. The TGA has conducted their site audit and the Directors have no reason to believe that the Company will be unsuccessful in achieving compliance with the Code.

**Further Comments:**  
Dr Paul D'Sylva  
Managing Director  
PharmAust Limited  
P: (03) 9565 1111  
M: 0410 602 586

**Media Enquiries:**  
Sarah Allchurch  
Allchurch Communications  
P: (08) 9381 6625  
M: 0412 346 412

**PharmAust Manufacturing Pty Ltd** manufactures and markets non-therapeutic and therapeutic pharmaceutical products for the Australian market.

The generic drug market is expected to grow to AU\$1.8b of the rapidly growing AU\$5.5b Pharmaceutical Benefits Scheme drug market in Australia. PharmAust is positioning itself as a key player to capture a share of this market.

PharmAust Manufacturing will commence manufacturing its full suite of therapeutic products registered on the Australian Register of Therapeutic Goods ("ARTG"), at its new facilities in Welshpool, Western Australia. PharmAust Manufacturing currently has a suite of 95 products on the ARTG along with over 200 non-therapeutic products in areas such as personal care products, cosmetics and galenicals.

PharmAust Manufacturing intends to progress its Channel Agreement with Xepa-Soul Pattinson for the registration and distribution of Xepa's generic prescription drugs along with PharmAust's own over-the-counter products. The preparation of applications to register three drugs in anti-allergy and gastro-oesophageal reflux therapeutic categories is underway.

It is anticipated these applications will represent the first in a series of registrations to be conducted over 2006/2007 for generic medicines initially in five different therapeutic categories being anti-infectives, anti-virals, anti-allergy, antacid and gastro-oesophageal reflux disease. PharmAust plans to register further products over the next three years as a number of key drug patents expire.

## **About PharmAust Limited**

PharmAust Limited is a vertically integrated pharmaceutical Group of companies involved in a range of activities from contract drug discovery and development to manufacturing, sales and marketing of healthcare & pharmaceutical products.

PharmAust wholly owns three main operating subsidiary companies:

### **Epichem Pty Ltd**

Epichem provides synthetic and medicinal chemistry services, primarily on a contract basis, to the drug discovery and pharmaceutical industries both in Australia and overseas. With two state of the art laboratories in Perth and Melbourne, it has some of the best equipment available for the cost effective synthesis of analogue libraries, intermediates and standards. In addition to its revenue generating contract work, Epichem also undertakes some internal and collaborative research into drug discovery.

### **Mimotopes Pty Ltd**

Mimotopes is a recognised leader in the development of pre-clinical peptides for biological and pharmaceutical applications. Established in Melbourne, Australia in 1988, Mimotopes also has sales offices and distribution channels in the US, UK, Europe, Japan, India and China. Mimotopes' strong proprietary intellectual property position, coupled with the extensive experience and in-depth know-how of its highly trained staff, make it a partner of choice for leading research and discovery companies.